Author:
Pietschke Katharina,Amaral Teresa,Sanchez Stephanie,Forchhammer Stephan,Flatz Lukas,Forschner Andrea
Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Jung W, Trümper L (2008) Differenzialdiagnose und -abklärung von Lymphknotenvergrößerungen. Internist 49(3):305–320
2. Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K (2020) The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett 25(1):1–14
3. Leitlinienprogramm Onkologie (2020) S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, S 1–281
4. Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L (2019) Checkpoint inhibitors. Dtsch Arztebl Int 116(8):119–126
5. Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N et al (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29(9):1895–1902